Linda Bolton-Weiser: Yes. Hi. So, it seems like on the drug shortage issue that we have seen some news articles and developments about Novo Nordisk actually starting to file suit against compounders. And my understanding, without being a drug analyst, my understanding is that when that happens it’s like a sign that their supply is ramping up adequately, when they start to crack down on these compounders. So I guess then I’m surprised to hear this about the shortages when it seems like actually the news was to the contrary, that there would be increased supply. So can you just comment on that? Yes. supply. Can you just comment on that?
Sima Sistani: Yes. Look, I mean, NOVO has been public in saying that they’re still seeing will go be at 0.25, 0.5, and 1 shortages through September. They’ve also said that sex sender old dosages through the end of 2023 and beyond. Your guess is as good as mine, I think, in terms of what they’re, the kind of going after compounder says. But frankly, my perspective on it is there’s a lot of misinformation, there are a lot of bad actors, and when people have poor results on the compounded substances, they then use the brand names, or quote unquote weight loss medications out in the market to explain their side effects and their issues. And it actually has nothing to do with their products. So, I think it’s a sound strategy on their part, but we can confirm that the shortages are still very much being felt in the market, and I’m happy that there is a broader strategy to reel in the bad actors.
Linda Bolton-Weiser: Okay. And can I also ask just about your trend of return to member growth? Are you able to say like which months it turned positive year-over-year? And is there any trend of acceleration of year-over-year growth, or is it just steady, or is it kind of just variable month-to-month? Is there any way you can tell us how the trend is going?
Sima Sistani: Hi, Linda. I think we’re seeing continued improvement in our trends through the course of the year. I wouldn’t want to pinpoint a specific moment in time, but recall we had our, solid step up in subscribers out of Q4 2022 and into Q1, and again now here in Q2 we’re ending with a step up out of Q1 for the first time in history. This is all pointing towards continued progress on the step change we’re making towards growing our subscriber base. Hopefully that helps.
Heather Stark: And I’ll just add, hey, what this is saying is the changes we’re making are working. I’ve said it from the beginning, activation rate is a leading indicator, and that number continues to smile. So we are really excited about what’s to come. We haven’t even introduced our biggest features yet and, we’ve noted that the progress and trends and what to eat tab are coming in the fall. And so, this is us leading with a digital first experience and really putting our data informed learnings to work.
Linda Bolton-Weiser: Okay. Thank you. That’s it for me.
Sima Sistani: Thank you.
Operator: The next question comes from Michael Lasser of UBS. Please go ahead.
Isabel Thompson: Hi, everyone. This is Isabel Thompson. I’m for Michael Lasser. Thank you for taking our question. Maybe just in the second quarter alone, there was only a modest increase in those clinical members since the acquisition closed. Were the supply constraints the only reason these subscribers haven’t been ramping faster or were there other factors at play here? And how do you plan to put marketing behind the Sequence business moving forward?
Sima Sistani: Isabel, thanks for your question. So I’ll start by saying I disagree that 40% uptick since acquisition is modest. But I will note is that we also saw that traction in a environment of supply shortages. And that really, again, again goes to reflecting our ability to help members through our wide formulary and through our customer, through our care program, the Sequence program. And I want to emphasize that we have these really big synergies. We’re able to provide solutions across the Weight Health spectrum. Now combining both the lifestyle intervention of Weight Watchers with clinical care. On the tech side, we’re combining billing, creating one identity through all channels. And to your question regarding we’re starting to marketing.
That’s also another important synergy where we’re going to have TAC efficiencies between our solutions. We have demonstrated ability to drive interest from people on our site to the clinical intervention and our initial tests and performance marketing. And again, we’re not standing here on top of funnel, because we want to ensure we protect the NPS during the supply shortages. But we’ve been testing and we can see that the combination of Weight Watchers alongside the Sequence brand has really improved ROIs. So we expect to really do more of that when the macro environment has improved.
Isabel Thompson: Thank you. That’s very helpful. And then maybe as a follow-up, are you doing any discounting of the core program to drive sign-ups higher there? And then, separately, do you have a sense of how many new and existing members are currently taking GLP-1 prescriptions?
